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Purpose: While chronic glucocorticoid (GC) therapy leads to ocular hypertension in about one third of individuals, almost
all  primary  open-angle  glaucoma  (POAG)  patients  show  this  response  and  are  called  “steroid  responders.”  Two
differentially spliced isoforms of the glucocorticoid receptor (GR), GRα and GRβ, regulate GC responsiveness in
trabecular meshwork (TM) cells. GRβ acts as a dominant negative regulator of GC activity and is expressed at lower levels
in glaucomatous TM cells, making them more sensitive to GCs. Several arginine/serine-rich splicing factor (SR) proteins
have been implicated in alternative splicing of the GR. We have previously demonstrated that immunophilins FKBP5 and
FKBP4 are required for GRα and GRβ translocation into the nucleus, which is essential for their biologic activity. The
purpose of the present study was to use single nucleotide polymorphism (SNP) genotyping to determine whether there
are any allele frequency differences in GR, FKBP4/5, or SR genes between normal control, POAG, and steroid responder
populations.
Methods: Clinically characterized individuals (400 normal controls, 197 POAG, and 107 steroid responders) were
recruited from the U. Iowa Ophthalmology Clinics after IRB approved consent. Genotyping of DNA samples for 48 SNPs
in SFRS3, SFRS5, SFRS9, FKBP4, FKBP5, and NR3C1 was done at GeneSeek using a mass spectroscopy based system.
Results: All 48 SNPs displayed high call rates (99%). There were no significant differences in allele frequencies or
genotypes in SNPs for SFRS5, SFRS9, FKBP4, FKBP5, and NR3C1 between the 3 groups. Up to three SNPs in SFRS3
had p-values <0.05 when comparing controls to POAG or steroid responders, but this statistical significance was lost when
the p values were adjusted for multiple measures.
Conclusions: Although these 6 genes may be involved in the pathogenesis of GC-induced ocular hypertension, it does
not appear that major heritable risk alleles in these genes are responsible for the development of GC-induced ocular
hypertension or POAG.
Glaucomatous optic neuropathy is a leading cause of
irreversible vision loss and blindness in the world. Primary
open-angle glaucoma (POAG) is one of the most prevalent
forms of glaucoma, and several of the risk factors involved in
POAG include family history, elevated intraocular pressure
(IOP), age, race, and responsiveness to glucocorticoids (GCs).
Heredity is a major risk factor in POAG [1], and several
glaucoma loci have been mapped and several genes identified
[2,3]. Elevated IOP, which is due to a compromised aqueous
humor outflow facility at the trabecular meshwork (TM), is
the primary risk factor associated with the development and
progression of glaucoma [4,5].
The therapeutic use of GCs can lead to the development
of ocular hypertension and iatrogenic open-angle glaucoma in
susceptible individuals. This secondary glaucoma clinically
mimics  many  features  of  POAG.  Although  only
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approximately  30%–40%  of  the  normal  population  are
“steroid  responders”  (i.e.,  develop  glucocorticoid-induced
ocular  hypertension),  most  of  POAG  patients  are  steroid
responders. Normal individuals who are steroid responders
are at higher risk for subsequently developing POAG [6,7],
and  steroid  responsiveness  appears  to  also  be  heritable
[8-10]. In addition, there have been reports suggesting that
endogenous cortisol may play a role in the pathogenesis of
POAG [11-13].
There  are  multiple  isoforms  of  the  glucocorticoid
receptor (GR) [14]. GRα is the ligand binding form of the
receptor  that  is  responsible  for  the  physiologic  and
pharmacological  effects  of  GCs.  GRβ  is  an  alternatively
spliced form of the receptor, which lacks the conventional
ligand binding domain, does not bind GCs, and acts as a
dominant negative regulator of GC activity [15,16]. Increased
expression of GRβ has been implicated in the development of
several steroid resistant diseases [17,18]. More germane to
glaucoma,  recent  work  in  our  laboratory  has  shown  that
glaucomatous TM cells have lower levels of GRβ compared
to normal TM cells, and this appears to be responsible for
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596increased GC sensitivity in the glaucomatous TM cells [19].
Levels and activities of these GR isoforms are regulated by
alternative splicing as well as by nuclear translocation of the
receptors. A variety of proteins and RNAs are involved in
alternative  splicing  of  gene  transcripts  [20],  and  the
splicesome proteins SFRS9 [21] and SFRS5 [22] are involved
in  alternative  splicing  of  the  GR.  In  addition,  the
immunophilins FKBP4 and FKBP5, along with other factors
such as Hsp90, are responsible for the nuclear translocation
of GRα and GRβ, respectively [23].
The  purpose  of  the  present  study  was  to  determine
whether  common  polymorphisms  in  several  of  the  genes
responsible  for  GC  activity  are  involved  in  steroid
responsiveness  and/or  POAG.  Single  nucleotide
polymorphism (SNP) genotyping has been successfully used
to identify several risk alleles and disease associated genes
[24-26], so we have used this technology to evaluate potential
involvement  of  common  alleles  in  genes  for  the
glucocorticoid  receptor  (NR3C1),  immunophilins  (FKBP4
and FKBP5), and SR splicesome proteins (SFRS3, SFRS5,
SFRS9)  in  the  development  of  GC-induced  ocular
hypertension and POAG.
METHODS
The  study  was  approved  by  the  University  of  Iowa’s
Institutional  Review  board  and  informed  consent  was
obtained from study participants. The study included a cohort
of 107 subjects that have a history of steroid-induced ocular
hypertension,  197  subjects  with  POAG,  and  400  normal
control  subjects  that  were  all  recruited  from  the
Ophthalmology Clinics at the University of Iowa (Iowa City,
IA).  The  majority  of  patients  were  Caucasian  with
approximately equal numbers of males and females in each
group.
The cohort of glaucoma patients underwent complete
ophthalmologic evaluation including slit lamp examination,
Goldmann  applanation  tonometry,  gonioscopy,  perimetry,
dilated stereoscopic examination of the optic nerve heads, and
optic nerve head photography. Visual fields were assessed
using  the  SITA  24–2  program  on  the  Humphrey  Field
Analyzer (Humphrey-Zeiss, Dublin, CA). Patients who were
unable to reliably perform automated perimetry were tested
with  Goldmann  manual  kinetic  perimetry  (Haag-Streit
Instruments, Koeniz, Switzerland) using the Armaly-Drance
protocol.
Patients were considered to have primary open angle
glaucoma regardless of IOP if they had open iridocorneal
angles, and evidence of glaucomatous optic nerve damage in
at least one eye. Those with evidence of a secondary etiology
of glaucoma such as pigment dispersion, pseudoexfoliation,
inflammation, or a history of glucocorticoid therapy were
excluded. Glaucomatous optic nerve damage was based on
both optic nerve and visual field examination. Glaucomatous
optic nerves had cup-to-disc ratios of greater than 0.7 with
thinning of the neural rim, asymmetry of the optic nerve cup-
to-disc  ratio  of  >0.2,  or  photographic  documentation  of
progressive loss of the neural rim. Patients were required to
have visual fields of adequate quality for interpretation. For
Humphrey visual fields this required a false positive rate, false
negative rate and fixation loss rate of less than 33% [27].
Humphrey visual field evidence of glaucoma was based on
the Collaborative Normal Tension Glaucoma Treatment Trial
criteria  [28].  Patients  evaluated  using  manual  kinetic
perimetry were required to exhibit depression of the visual
field  in  an  arcuate  pattern  respecting  the  nasal  horizontal
meridian.
Corticosteroid  responders  included  patients  who
exhibited an elevation of IOP of more than 5 mmHg after
administration  of  glucocorticoid  steroids  (prednisolone
acetate,  dexamethasone,  prednisolone  phosphate,
fluorometholone, betamethasone, or oral prednisone) for at
least 4 weeks or who exhibited glaucomatous optic nerve
damage (as defined above) after a prolonged course of oral or
topical glucocorticoids.
The  normal  controls  were  obtained  from  the
Comprehensive Ophthalmology Clinic at the University of
Iowa. These subjects were all over age 59 and had no history
of glaucoma and no family history of glaucoma. They had a
normal slit lamp and optic nerve head examination. They were
not tested for steroid responsiveness.
A total of 48 SNPs were selected using HapMap data to
maximize the power to detect an association using the UCLA
Association Study Design Server online software package.
Tag SNPs were selected using HapMap data to maximize the
statistical power with this software as previously described
[29]. The cohorts were genotyped at 4 SNPs within SFRS3, 5
SNPs within SFRS5, 5 SNPs within SFRS9, 3 SNPs within
FKBP4, 10 SNPs within FKBP5, and 21 SNPs within NR3C1
using  a  mass  spectroscopy-based  system  (Sequenom,  San
Diego, CA). Genotyping was conducted using theMassArray
platform and iPlex Gold reagents with the manufacturer’s
protocol by GeneSeek (Lincoln, NE). SNP allele frequencies
were compared between subjects and controls using Fisher’s
exact  test.  Genotype  frequencies  were  compared  using  χ2
analysis. For rare variants for which the χ2 test was unsuitable,
we used Fisher’s exact test. P-values were calculated using R
2.10.1. The Bonferroni correction was used to adjust p-values
for multiple measures as needed.
Power for the current study was estimated by simulation
for different values of minor allele frequency and disease odds
ratio (OR) for having an additional copy of a disease allele.
Simulated data were fitted using a logistic regression in which
the explanatory variable is genotype coded as 0, 1, or 2. The
power is computed as the proportion the slope estimate is
significantly  different  from  0  at  level  0.05  out  of  10,000
simulation replicates.
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A cohort of 107 subjects with a history of steroid-induced
ocular hypertension (steroid-responders), 197 POAG patients,
and 400 control subjects from Iowa were genotyped at a total
of 48 SNPS in SFRS3, SFRS5, SFRS9, FKBP4, FKBP5, and
NR3C1. Given the size of our cohort, we have adequate power
under most conditions to detect powerful risk factors for the
steroid response or POAG that have an odds ratio of greater
than 1.75. High call rates (mean 99%) were obtained at these
SNPs, which have an average spacing of 7.1 kb. Comparisons
of allele frequencies and genotype frequencies of these SNPs
were  made  between  the  steroid-responders  and  control
subjects and also between POAG patients and normal subjects
(Table 1). There was no significant difference in the allele
frequencies or genotypes of SNPs in SFRS5, SFRS9, FKBP5,
TABLE 1. SNP GENOTYPING RESULTS.
          p-values (allele frequency) p-values (genotype frequency)
Gene SNP ID Location (bp) Spacing
(bp)
Minor Allele
Frequency
NL versus
Steroid
Responders
NL versus
POAG
NL versus
Steroid
Responders
NL versus
POAG
SFRS3 rs7759778 36660245 10174 0.25 0.084 0.77 0.046 0.10
  rs1406945 36670419 7925 0.283 0.027 0.043 0.033 0.036
  rs7344 36678344 10783 0.217 0.11 0.11 0.011 0.073
  rs13202984 36689127   0.292 0.15 0.27 0.33 0.44
SFRS5 rs7153985 69296240 9254 0.117 0.13 0.59 0.36 0.17
  rs3104 69305494 4185 0.317 0.86 0.83 0.84 0.94
  rs8019166 69309679 3579 0.195 0.34 0.86 0.26 0.74
  rs4646296 69313258 4853 0.059 0.46 0.71 0.38 0.87
  rs17556915 69318111   0.175 0.30 0.41 0.37 0.64
SFRS9 rs2235222 119376576 3096 0.13333 0.37 0.94 0.53 0.60
  rs3847971 119379672 4985 0.35833 0.63 0.48 0.74 0.76
  rs9040 119384657 992 0.3 0.56 0.32 0.39 0.58
  rs7027 119385649 10520 0.15 0.27 0.14 0.68 0.37
  rs540520 119396169   0.28333 0.30 0.34 0.36 0.54
FKBP4 rs2968909 2768125 3706 0.15833 0.013 0.24 0.40 0.47
  rs3759411 2771831 6156 0.1 0.051 0.51 0.87 0.67
  rs1981655 2777987   0.05833 0.22 0.73 0.18 0.72
FKBP5 rs755658 35657648 12970 0.05833 0.17 0.83 0.35 0.92
  rs3798346 35670618 334 0.325 0.40 0.55 0.66 0.60
  rs9366890 35670952 4108 0.175 0.92 0.87 0.96 0.97
  rs9296158 35675060 2199 0.24167 0.56 0.55 0.56 0.59
  rs4713899 35677259 6206 0.15 0.92 >0.99 0.74 0.55
  rs737054 35683465 3515 0.225 0.26 0.68 0.24 0.26
  rs3777747 35686980 10068 0.43333 0.54 0.90 0.41 0.74
  rs9380524 35697048 28515 0.14167 0.23 0.24 0.46 0.46
  rs6912833 35725563 4336 0.24167 0.88 0.46 0.18 0.67
  rs17614642 35729899   0.13333 >0.99 >0.99 0.64 0.81
NR3C1 rs174048 142630597 4611 0.18333 0.30 0.19 0.40 0.26
  rs17287745 142635208 2006 0.39167 0.43 0.90 0.67 0.57
  rs17287758 142637214 12202 0.15833 0.91 0.79 0.44 0.45
  rs17209251 142649416 1085 0.20833 0.52 0.77 0.75 0.88
  rs10482672 142672726 4762 0.14167 0.59 0.60 0.51 0.62
  rs33388 142677488 26078 0.45833 0.76 0.42 0.68 0.39
  rs2918418 142703566 7003 0.175 0.41 0.15 0.64 0.37
  rs4912905 142710569 25628 0.23333 0.93 0.15 0.41 0.27
  rs2963155 142736197 11736 0.3 0.11 0.34 0.19 0.13
  rs9324921 142747933 13827 0.05833 0.72 0.35 0.88 0.39
  rs10482616 142761760 10917 0.125 0.67 0.54 0.53 0.57
  rs9324924 142772677 166 0.31667 0.52 0.11 0.75 0.18
  rs7701443 142772843 2075 0.29167 0.94 0.24 0.98 0.45
  rs4244032 142774918 1807 0.21667 0.70 0.44 0.76 0.51
  rs4607376 142776725 4948 0.45 0.19 >0.99 0.30 0.73
  rs13182800 142781673 4422 0.16667 0.70 0.76 0.80 0.79
  rs12054797 142786095 1130 0.24167 0.45 0.090 0.74 0.31
  rs12656106 142787225 1915 0.3 0.62 0.15 0.85 0.25
  rs12656106 142789140 8660 0.4833 0.82 0.67 0.96 0.89
  rs12521436 142797800 699 0.175 0.36 >0.99 0.29 0.97
  rs4912913 142798499   0.4833 0.94 >0.99 0.37 0.31
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598and NR3C1 between patients and the control subjects (p>0.05
uncorrected for multiple measures).
When the genotype frequencies of four SNPs in SFRS3
were  compared  between  steroid-responders  and  control
subjects,  3  contiguous  SNPs  (rs7759778,  rs1406945,  and
rs7344) produced p-values <0.05 (uncorrected for multiple
measures). Similarly, an uncorrected p-value of 0.036 was
produced when the genotypes were compared between POAG
patients and control subjects at one of these SFRS3 SNPs
(rs1406945). Comparison of allele frequencies at rs1406945
also  produced  uncorrected  p-values  <0.05.  Finally,
comparison of the allele frequencies of a single SNP in FKBP4
(rs2968909) between steroid responders and control subjects
produced  a  p-value  of  0.013.  The  allele  and  genotype
frequencies of these SNPs are shown in Table 2. However,
when  adjusted  for  multiple  measures  with  a  Bonferroni
correction, none of these p-values is statistically significant.
DISCUSSION
Glucocorticoid administration can elevate IOP in susceptible
individuals that can lead to the development of an iatrogenic
secondary  open-angle  glaucoma  that  mimics  POAG  [30].
Only a subset of normal individuals have the propensity to
develop  steroid-induced  ocular  hypertension.  In  contrast,
most  POAG  patients  are  steroid  responders,  and  POAG
patients have also been reported to have greater sensitivity to
cutaneous  GC  vasoconstriction  [31].  However,  the  exact
molecular  mechanism(s)  responsible  for  steroid
responsiveness is currently unclear.
One potential explanation for altered GC sensitivity is
inter-individual differences in the expression levels of GRβ,
the dominant negative isoform of the GR. There have been
numerous reports of the potential involvement of GRβ in GC
resistant  diseases  such  as  inflammatory  bowel  syndrome,
rheumatoid arthritis, and asthma, among others [17,18]. We
have shown that TM cells derived from glaucomatous donors
have lower levels of GRβ compared to normal TM cells and
that GRβ levels regulate TM responses to dexamethasone,
such  as  induction  of  myocilin,  fibronectin,  and  GRE-
luciferase as well as inhibition of TM cell phagocytosis [19,
32]. Alternative splicing of GR is regulated by specific SR
splicesome proteins [21,22]. In addition, translocation of both
GRα and GRβ to the nucleus is essential for the biologic
activities  of  these  receptor  isoforms,  and  immunophilins
FKBP5  and  FKBP4,  along  with  other  cofactors,  are  co-
chaperones for this GRβ and GRα translocation [23].
Despite evidence implicating the involvement of GRβ in
the steroid responsiveness and POAG, it does not appear that
major  heritable  risk  alleles  in  genes  encoding  GR,  GR
splicesome proteins, or GR nuclear translocation proteins are
involved in the development of these conditions. Although
there was a suggestion that genotypes and allele frequencies of
SFRS3  SNPs  may  be  different  in  steroid  responders  and
POAG  patients  compared  to  ethnically-matched  controls,
these  allele  frequencies  were  not  statistically  significant
different when corrected for multiple measures. These data
suggest that ancestral mutations in SFRS3, SFRS5, SFRS9,
FKBP4, FKBP5, and NR3C1 are not strong risk factors for
disease. Our study was adequately powered to identify strong
risk factors for the steroid response or POAG (odds ratio
>1.75). However, the suggestive p-values obtained in our
TABLE 2. GENOTYPE AND ALLELE FREQUENCIES OF INFORMATIVE SNPS.
rs7759778
Genotype Norm POAG SR   Allele Norm POAG SR
C 237 121 58   C 613 300 152
CG 139 58 36   G 177 90 60
G 19 16 12   Total 790 390 212
(blank) 5 2 1          
Grand Total 400 197 107          
rs1406945
Genotype Norm POAG SR   Allele Norm POAG SR
C 200 88 45   C 568 261 138
GC 168 85 48   G 216 131 76
G 24 23 14   Total 784 392 214
(blank) 8 1 0          
Grand Total 400 197 107          
rs7344
Genotype Norm POAG SR   Allele Norm POAG SR
C 12 14 11   C 156 93 53
TC 132 65 31   T 638 299 161
T 253 117 65   Total 794 392 214
(blank) 3 1 0          
Grand Total 400 197 107          
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599studies  of  SFRS3  might  be  further  pursued  with  a  larger
focused association study with power to detect variations that
confer modest risk for steroid responsiveness or POAG. Also,
it remains possible that non-ancestral variations in these genes
(that cannot be detected by association studies) may confer
risk for steroid responsiveness or POAG.
Another recent study examined GR polymorphisms in
patients  who  had  received  intravitreal  triamcinolone
injections  [33].  There  were  no  statistically  significant
associations between any of the 6 tested GR polymorphisms
and  the  magnitude  of  IOP  elevation  in  these  patients.
However, only 52 patients were evaluated in this study, some
of whom were steroid responsive and others non-responsive
(although the number of responders was not disclosed), so
only a very strong risk correlation would have been identified.
In our study, we examined a larger number of characterized
steroid responders with 21 SNPs spanning the GR gene, and
we  also  did  not  find  an  association.  However,  these  two
studies differ in several ways. In our study, we had more
steroid responders (n=107), but we did not have access to
significant  numbers  of  clinically  characterized
nonresponders.  We  therefore  had  to  compare  the  steroid
responder population with the normal control population, a
significant minority of which are most likely untested steroid
responders  (approximately  30%),  which  makes  it  more
difficult to see a correlation between these two groups.
Currently, the propensity to develop GC-induced ocular
hypertension must be determined empirically. Therefore, all
patients on protracted GC therapy should have their IOPs
monitored periodically throughout the course of GC therapy.
In addition, patients who are documented steroid responders
have a higher risk for developing POAG. Therefore, there is
a definite need for a reliable test that would predict steroid
responsiveness in patients. Unfortunately, it does not appear
that genetically screening for the SNPs in the genes evaluated
in our study will be useful markers to predict steroid-induced
ocular  hypertension  or  POAG,  at  least  in  the  current
population studied.
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